ISO/IEC 17025:2017 - Testing and Calibration Laboratories Lead Auditor Free Practice Test — 30 Questions

Question 1

A medical device company, \"MediCorp Solutions,\" is undergoing an ISO 13485:2016 audit. During the audit, the lead auditor, Ms. Anya Sharma, is reviewing MediCorp\'s risk management processes. She notes that MediCorp has meticulously documented risk assessments during the design and development phase of their new infusion pump, \"InfusaSafe,\" and has implemented robust risk control measures. However, Ms. Sharma finds that MediCorp\'s post-market surveillance plan for InfusaSafe is limited to passively collecting customer complaints through their website and has no active mechanism for systematically gathering data on device performance in real-world clinical settings. Considering the requirements of ISO 13485:2016 and the importance of continuous risk management, what is the MOST significant concern Ms. Sharma should raise regarding MediCorp\'s approach to risk management for InfusaSafe?

Accepted Answer

The lack of active post-market surveillance mechanisms may prevent MediCorp from identifying and addressing potential safety issues that emerge after the device is released, hindering continuous risk management as required by ISO 13485:2016.

Question 2

MediCorp, a multinational medical device manufacturer, produces a wide range of products, from diagnostic equipment to implantable devices. While certified to ISO 13485:2016, MediCorp is struggling to maintain consistent quality across all product lines and is facing increasing scrutiny from regulatory bodies, particularly concerning compliance with the European Medical Device Regulation (MDR). Internal audits reveal recurring issues with design validation for new products, supplier quality control, and post-market surveillance effectiveness. Senior management acknowledges that the current Quality Management System (QMS), while documented and implemented, seems inadequate to address the dynamic nature of the medical device industry and the increasingly stringent regulatory landscape. Given this scenario, which of the following approaches would be MOST effective for MediCorp to enhance its QMS and ensure sustained compliance and product quality, considering the requirements of ISO 13485:2016 and the MDR?

Accepted Answer

Implement a comprehensive, risk-based approach integrated throughout the entire product lifecycle, focusing on proactive risk analysis, robust risk control measures, continuous monitoring, and improvement based on post-market surveillance data.

Question 3

Dr. Anya Sharma, the Quality Manager at MediCorp Devices, is overseeing a change to the sterilization process for their line of implantable cardiac pacemakers. The current sterilization method is being replaced with a faster, more cost-effective technique. According to ISO 13485:2016, what is the MOST critical element that Dr. Sharma must ensure is thoroughly addressed during the change management process BEFORE implementing the new sterilization technique, to maintain compliance and ensure product safety and efficacy? The company has already documented the change and received preliminary approval from the engineering department.

Accepted Answer

A comprehensive impact assessment evaluating the potential effects on product performance, regulatory compliance, risk management, and the overall quality management system, with specific attention to the sterility assurance level (SAL).

Question 4

During an ISO 13485:2016 audit of \"MediCare Innovations,\" a medical device manufacturer specializing in implantable cardiac pacemakers, the lead auditor, Dr. Anya Sharma, reviews the product realization planning documentation. The documentation meticulously outlines the process for determining product requirements, including detailed specifications based on customer needs identified through market research and compliance with relevant regulatory standards such as the European Medical Device Regulation (MDR) and FDA regulations. The documentation also covers the validation and verification activities planned throughout the product lifecycle. However, Dr. Sharma notices a significant absence: there is no explicit mention or integration of risk management activities within the product realization planning process. While risk management is addressed as a separate process within the QMS, it\'s not directly linked to the planning of product realization activities. The company\'s rationale, according to the Quality Manager, Mr. Ben Carter, is that risk management is handled separately by the risk management department to ensure objectivity and independence. Considering the requirements of ISO 13485:2016, what should Dr. Sharma, the lead auditor, conclude regarding this approach?

Accepted Answer

Identify this as a nonconformity, as ISO 13485:2016 requires risk management to be integrated into the product realization planning process, not treated as a completely separate activity.

Question 5

StellarTech Medical, a US-based medical device manufacturer compliant with FDA regulations and certified to ISO 13485:2016, plans to expand its market into the European Union. To comply with the European Medical Device Regulation (MDR), StellarTech needs to enhance its post-market surveillance (PMS) system. As the Lead Auditor, you are tasked with advising StellarTech on how to best integrate its PMS activities with its existing risk management processes under ISO 13485:2016 to meet MDR requirements. Which of the following approaches would be most effective in achieving this integration, ensuring continuous improvement, and maintaining compliance? The integration must consider the entire lifecycle of the medical device, from design and development through post-market use, and must address the specific requirements of both ISO 13485:2016 and the MDR regarding risk management and post-market surveillance. The integration should enable StellarTech to proactively identify and mitigate potential risks, ensure the continued safety and effectiveness of its devices, and maintain compliance with regulatory requirements in both the US and the EU.

Accepted Answer

Establish a system for proactively collecting and analyzing post-market data (e.g., user feedback, complaints, adverse event reports) and integrating this data into the risk management process to update risk assessments and implement necessary corrective actions or design changes, ensuring continuous improvement and compliance with both ISO 13485:2016 and the MDR.

Question 6

MedTech Solutions, a manufacturer of Class II medical devices specializing in patient monitoring systems, is preparing for an ISO 13485:2016 surveillance audit. They source several critical components from external suppliers, including microcontrollers for data processing, sensors for physiological measurements, and power supplies for device operation. The company has a documented supplier management process, but the internal audit team has raised concerns about the depth of risk assessment applied to different suppliers. Specifically, they question whether the controls applied to each supplier are commensurate with the potential impact of their supplied components on the safety and performance of the monitoring systems. Considering the requirements of ISO 13485:2016, what is the MOST critical aspect MedTech Solutions should focus on to address the internal audit team\'s concerns regarding supplier management?

Accepted Answer

Implementing a risk-based approach to supplier quality assurance, ensuring that the type and extent of controls applied to suppliers are proportionate to the risk associated with their products or services, considering factors such as criticality of the component, supplier's QMS maturity, and past performance.

Question 7

\"MediCore Devices,\" a manufacturer of Class III implantable cardiovascular devices, is undergoing its annual ISO 13485:2016 surveillance audit. During the audit, the auditor, Ms. Anya Sharma, reviews MediCore\'s supplier management processes. She notes that while MediCore has a documented supplier evaluation and selection process, there is limited evidence of proactive risk assessments conducted on its critical suppliers of biocompatible polymers used in the device\'s construction. These polymers are sourced from three different suppliers located in geographically diverse regions. MediCore\'s quality manager, Mr. Ben Carter, explains that all suppliers are ISO 9001 certified and have consistently met the required specifications. However, Ms. Sharma emphasizes the need for a more comprehensive risk-based approach aligned with ISO 13485:2016 requirements. Considering the criticality of the biocompatible polymers and the potential impact on device safety and patient health, what specific action should MediCore Devices prioritize to address this audit finding and ensure compliance with ISO 13485:2016 regarding supplier management?

Accepted Answer

Conduct and document a comprehensive risk assessment of each supplier of biocompatible polymers, considering factors such as their QMS maturity, criticality of the material, historical performance, and geographical location, and use the assessment results to determine the appropriate level of control and monitoring.

Question 8

Dr. Anya Sharma leads the design and development team at MedTech Innovations, a company specializing in implantable cardiac devices. During a recent internal audit focused on ISO 13485:2016 compliance, a potential gap was identified in how risk management is integrated into the design and development process. Specifically, the audit revealed that while initial risk assessments are conducted, the verification of the effectiveness of risk control measures is not consistently documented, and post-market surveillance data isn\'t systematically fed back into the design process to update risk assessments. Furthermore, there is a lack of clarity regarding the criteria used to determine acceptable risk levels for different device functionalities. Considering ISO 13485:2016 requirements, what is the MOST critical area Dr. Sharma should prioritize to address this gap and ensure ongoing compliance and product safety?

Accepted Answer

Establishing a documented process for verifying the effectiveness of risk control measures implemented during design and development, ensuring post-market surveillance data is integrated into risk assessments, and defining clear, justifiable criteria for acceptable risk levels.

Question 9

MedTech Solutions, a manufacturer of implantable cardiac pacemakers, is undergoing an ISO 13485:2016 audit. The auditor, Ms. Ishikawa, is reviewing the company\'s risk management process. She observes that while the company has conducted thorough risk assessments during the design and development phase, the post-market surveillance data collection primarily focuses on device malfunctions reported through mandatory adverse event reporting channels. There is limited evidence of proactive data collection from patient registries, clinician feedback, or analysis of explanted devices. Furthermore, the risk management documentation lacks a clear link between post-market surveillance findings and updates to the design or manufacturing processes. Considering ISO 13485:2016 requirements, what is the most significant area of concern regarding MedTech Solutions\' risk management approach?

Accepted Answer

The inadequate integration of post-market surveillance data into the overall risk management process, potentially leading to a failure to identify and address evolving risks associated with the pacemaker throughout its lifecycle.

Question 10

MedTech Solutions, a manufacturer of Class II medical devices, is undergoing an ISO 13485:2016 audit. During the audit, the lead auditor, Ms. Anya Sharma, reviews the company\'s risk management documentation for their newly released infusion pump. She observes that while the initial risk assessment during design and development was comprehensive, there is a lack of documented evidence showing how post-market surveillance data, including user complaints, device malfunctions reported through their customer service channels, and adverse event reports submitted to regulatory authorities, are systematically integrated back into the risk management process to update risk assessments and control measures. The company\'s procedure mentions post-market surveillance data collection, but there is no clear process for feeding this information back into the risk management activities. According to ISO 13485:2016, what is the MOST critical deficiency in MedTech Solutions\' risk management system concerning post-market surveillance?

Accepted Answer

The risk management process does not incorporate a feedback loop from post-market surveillance to ensure continuous improvement and risk mitigation.

Question 11

Dr. Anya Sharma, the Quality Manager at \"MediTech Innovations,\" a manufacturer of implantable cardiac pacemakers, is tasked with enhancing the company\'s risk management process according to ISO 13485:2016. MediTech has a robust system for initial risk analysis and control during the design and development phase, including FMEA (Failure Mode and Effects Analysis) and fault tree analysis. However, recent internal audits have revealed a disconnect between the post-market surveillance data collected and its integration into the ongoing risk management activities. Specifically, customer complaints regarding battery life and occasional malfunctions are not systematically feeding back into the risk assessment process to update probabilities and severity estimates. Considering ISO 13485:2016 requirements, which approach would most effectively improve MediTech\'s risk management system to ensure continuous improvement and patient safety?

Accepted Answer

Establishing a closed-loop system where post-market surveillance data, including customer complaints and adverse event reports, is systematically analyzed and used to update risk assessments, refine risk control measures, and inform design improvements.

Question 12

MediCorp Solutions, a medical device manufacturer specializing in implantable cardiac devices, is facing challenges with its post-market surveillance process. While the company diligently collects data from various sources, including customer complaints, field service reports, and regulatory databases, they are struggling to effectively analyze this information to proactively identify potential safety issues or performance trends related to their marketed devices. The current system lacks a structured approach, resulting in delayed identification of potential problems and reactive responses to incidents. Senior management is concerned about potential non-compliance with ISO 13485:2016 requirements for post-market surveillance.

As a lead auditor assessing MediCorp Solutions\' QMS, which of the following recommendations would be MOST effective in addressing their post-market surveillance data analysis challenges and ensuring compliance with ISO 13485:2016?

Accepted Answer

Implement a structured methodology for analyzing post-market data, including establishing clear data analysis procedures, defining key performance indicators (KPIs), utilizing statistical techniques to identify trends, and establishing a risk-based approach to prioritize issues.

Question 13

MediCorp, a manufacturer of implantable cardiac pacemakers, faces a critical challenge. Their primary microchip supplier has announced the discontinuation of a key component used in the pacemaker\'s circuitry. To maintain production, MediCorp engineers have redesigned the circuit to accommodate a functionally equivalent, but physically different, microchip from an alternative supplier. As a lead auditor assessing MediCorp\'s compliance with ISO 13485:2016, which of the following actions *most completely* reflects the necessary steps MediCorp *must* undertake to ensure continued compliance and patient safety given the component change? Consider the regulatory implications, design control requirements, and risk management principles inherent in ISO 13485:2016. The scenario involves a significant change to a critical component in a high-risk medical device, so the correct answer must address all relevant aspects of the standard.

Accepted Answer

Conduct a documented impact assessment of the circuit redesign on the pacemaker's safety and performance, perform thorough verification and validation testing of the redesigned pacemaker, and notify relevant regulatory bodies of the design change before market release.

Question 14

MedTech Solutions, a manufacturer of Class II medical devices, has recently implemented a significant software update to its embedded system controlling the vital signs monitoring equipment. This update is intended to enhance the device\'s data processing speed and improve the user interface based on feedback from healthcare professionals. However, the software update also involves changes to the algorithms used for calculating critical parameters such as heart rate variability and blood oxygen saturation. As a Lead Auditor evaluating MedTech Solutions\' compliance with ISO 13485:2016, what is the MOST critical action the company should undertake as part of its change management process to ensure continued compliance and product safety following this software update?

Accepted Answer

Conduct a comprehensive impact assessment, including testing to verify the software update's effect on the medical device's performance and safety.

Question 15

AquaTest Services, a water testing laboratory, is planning to implement a new, more sensitive method for detecting a specific emerging contaminant in drinking water. This new method has the potential to provide more accurate results but also carries the risk of generating false positives if not implemented correctly. Considering the requirements of ISO/IEC 17025:2017, what is the MOST important step AquaTest Services should take to manage the risks associated with this change and ensure the validity of its testing results?

Accepted Answer

Conduct a thorough validation of the new method, including comparison studies with the existing method, assessment of potential interferences, and training of personnel, before implementing it for routine testing.

Question 16

MedTech Solutions, a manufacturer of Class II medical devices, is preparing for an ISO 13485:2016 audit. During a preliminary review, the lead auditor, Dr. Anya Sharma, notes inconsistencies in the application of risk management principles across different stages of the product lifecycle for their flagship blood glucose monitoring system. While the design and development phase demonstrates a robust risk management process, the auditor observes limited evidence of risk assessment and mitigation in areas such as supplier management, production process validation, and post-market surveillance activities. Specifically, supplier audits do not consistently address potential risks related to component quality, process validation reports lack detailed risk assessments of potential failure modes, and post-market surveillance data analysis does not adequately address user feedback related to usability issues. Considering the requirements of ISO 13485:2016, which of the following statements best describes the correct application of risk management?

Accepted Answer

Risk management should be applied to all processes throughout the product lifecycle, encompassing design and development, production, service provision, post-market surveillance, and supplier management.

Question 17

Dr. Anya Sharma, the newly appointed Quality Manager at \"MediCorp Innovations,\" a manufacturer of advanced diagnostic imaging equipment, is tasked with implementing ISO 13485:2016. During her initial assessment, she observes that while the design and development team diligently performs risk analysis and mitigation activities as per the standard, other departments, such as production, supplier management, and post-market surveillance, lack formal documented risk management processes. The production team primarily focuses on meeting production targets, supplier management relies solely on supplier certifications, and post-market surveillance is limited to addressing customer complaints reactively. Dr. Sharma recognizes that this fragmented approach poses a potential compliance risk. According to ISO 13485:2016, which of the following statements best describes the required scope of risk management activities within MediCorp Innovation\'s Quality Management System?

Accepted Answer

Risk management activities must be integrated into all stages of the medical device lifecycle, including design and development, production, supplier management, and post-market surveillance, with documented processes and procedures for each stage.

Question 18

StructTest Ltd., an ISO/IEC 17025:2017 accredited materials testing laboratory, is seeking to expand its scope of accreditation to include a new mechanical testing method for composite materials. The laboratory has acquired the necessary equipment and trained its personnel but needs to demonstrate competence in performing the new method to the accreditation body. Considering the requirements of ISO/IEC 17025:2017, which of the following strategies represents the MOST effective approach for validating the new testing method and providing objective evidence of its reliability and accuracy to the accreditation body? The strategy should encompass a comprehensive validation process and documentation of results.

Accepted Answer

Developing a validation plan, conducting a validation study to determine the performance characteristics of the method (e.g., accuracy, precision, detection limit), analyzing the validation data statistically, and documenting the results in a validation report for submission to the accreditation body.

Question 19

\"Precision Instruments,\" a calibration laboratory accredited to ISO/IEC 17025:2017, is contracted by \"BioMed Innovations\" to calibrate their equipment used in the manufacturing of medical devices. \"BioMed Innovations\" must comply with ISO 13485:2016. During a routine audit of \"Precision Instruments,\" the auditor, Kenji Tanaka, notices that while \"Precision Instruments\" has a robust document control system, access to certain critical calibration procedures is not restricted based on user roles. Any technician, regardless of their training or authorization level, can modify these procedures. Kenji is concerned that this lack of access control could compromise the integrity of the calibration process and potentially impact the compliance of \"BioMed Innovations\" with ISO 13485:2016. Which of the following best describes the key concern related to document control in this scenario?

Accepted Answer

The lack of restricted access to critical calibration procedures could lead to unauthorized modifications, compromising the integrity of the calibration process.

Question 20

MedTech Solutions, a manufacturer of implantable cardiac pacemakers, is undergoing an internal audit of its Quality Management System (QMS) based on ISO 13485:2016. The audit team, led by senior auditor Anya Sharma, is reviewing the company\'s risk management processes. During the review, Anya discovers that while MedTech Solutions has meticulously documented risk analyses for the design and development phases of the pacemaker, there is a lack of documented evidence demonstrating the integration of post-market surveillance data back into the risk management process. Specifically, reports of adverse events and customer complaints related to battery life discrepancies are not being systematically analyzed to identify potential design flaws or manufacturing process variations that could contribute to the increased failure rate. Considering the requirements of ISO 13485:2016 and its emphasis on a lifecycle approach to risk management, what is the most significant nonconformity identified by Anya?

Accepted Answer

Failure to adequately integrate post-market surveillance data into the risk management process, potentially leading to an incomplete understanding of the device's overall risk profile and hindering continuous improvement efforts.

Question 21

MediCorp Innovations, a medical device manufacturer, is seeking to enhance its ISO 13485:2016 compliant Quality Management System (QMS). During a recent internal audit, a significant discrepancy was identified: While design phase risk assessments diligently identify potential hazards and implement mitigation strategies, post-market surveillance data reveals recurring incidents not predicted in the initial risk analyses. Specifically, users are reporting a higher-than-expected rate of a specific type of malfunction under certain environmental conditions not fully accounted for during design. The company\'s leadership recognizes the need to bridge this gap between theoretical risk assessment and real-world performance to ensure patient safety and maintain compliance. Which of the following actions would MOST effectively address this identified gap and improve the integration of risk management principles throughout MediCorp Innovations\' product lifecycle, in accordance with ISO 13485:2016 requirements?

Accepted Answer

Establish a formal feedback loop integrating post-market surveillance data into the risk management process, ensuring continuous refinement of risk assessments and proactive implementation of corrective actions based on real-world performance data.

Question 22

MediCorp Solutions, a medical device manufacturer, has established a Quality Management System (QMS) based on ISO 13485:2016. However, they are experiencing recurring issues with product nonconformities and delays due to supplier-related problems. Their current supplier management process includes initial supplier qualification based on documentation review and occasional audits. Despite this, they are still facing issues like inconsistent material quality and late deliveries, impacting their production schedule and product quality. Senior management is concerned about potential regulatory repercussions and increased costs associated with these supplier-related problems. What should MediCorp Solutions implement to proactively address these supplier-related challenges and ensure compliance with ISO 13485:2016 requirements for supplier management, going beyond their current initial qualification process?

Accepted Answer

Implement a comprehensive supplier risk management program, including regular risk assessments, performance monitoring, audits, and clear communication channels, integrated into the QMS.

Question 23

Dr. Anya Sharma leads the Quality Assurance department at MedTech Innovations, a company specializing in the design and manufacturing of implantable medical devices. MedTech Innovations is currently undergoing an internal audit to ensure compliance with ISO 13485:2016. During the audit, it is observed that while the company has a well-documented risk management process, the post-market surveillance data is not systematically integrated back into the risk management file. Customer complaints are addressed individually, and adverse event reports are filed separately, but there is no formal mechanism to analyze this data collectively to identify trends or emerging risks. The audit team raises a concern about the potential for unidentified hazards and the lack of continuous improvement in device safety.

Considering the requirements of ISO 13485:2016, what is the MOST significant implication of this gap in integrating risk management and post-market surveillance at MedTech Innovations?

Accepted Answer

The inability to proactively identify and mitigate emerging risks based on real-world device performance, potentially leading to undetected hazards and delayed corrective actions.

Question 24

A medical device manufacturer, \"MediCore Innovations,\" has successfully launched a new Class II medical device. After two years in the market, reports from clinicians indicate a higher-than-expected rate of device malfunction under specific environmental conditions not fully anticipated during initial design validation. The internal quality team at MediCore is now tasked with evaluating their adherence to ISO 13485:2016 concerning risk management. Considering the post-market data and the requirements of ISO 13485:2016, which of the following actions represents the MOST complete and compliant approach to addressing this situation and ensuring ongoing conformity to the standard\'s risk management expectations throughout the product lifecycle?

Accepted Answer

Initiating a comprehensive review of the original risk analysis, incorporating the new post-market data, updating risk control measures, and ensuring these updates are integrated into production, post-market surveillance, and change management processes.

Question 25

BioTech Solutions, a manufacturer of implantable cardiac pacemakers, has received a concerning increase in reported incidents of premature battery depletion in one of their flagship models, the \"PaceLife 3000,\" over the past six months. This trend has emerged from post-market surveillance data collected through patient feedback, physician reports, and device monitoring systems. The data suggests a potential systemic issue affecting battery performance, which could lead to device malfunction and necessitate premature replacement surgeries, posing a significant risk to patient safety. Considering the requirements of ISO 13485:2016 and the need for a proactive approach to risk management, what is the MOST appropriate initial action for the Quality Assurance Manager, Aaliyah Chen, to take in response to this emerging issue? Aaliyah understands the importance of acting swiftly but also needs to ensure the response aligns with regulatory requirements and minimizes potential disruptions. She needs to balance immediate action with a thorough and systematic investigation.

Accepted Answer

Conduct a comprehensive review and update of the PaceLife 3000's risk management file, incorporating the new post-market surveillance data to reassess existing risks and identify any previously unrecognized hazards related to battery performance.

Question 26

"PharmaSolutions," a manufacturer of pharmaceutical packaging, has conducted its annual management review meeting. During the meeting, the management team identified a recurring issue: corrective actions implemented in response to internal audit findings are often ineffective in preventing recurrence of the identified nonconformities. Ms. Grace Chen, the CEO, wants to ensure that future corrective actions are more effective.

According to ISO 13485:2016 requirements for management review outputs, which of the following decisions would be the MOST appropriate outcome of the management review meeting to address this specific issue?

Accepted Answer

Allocate resources for additional training on root cause analysis and corrective action implementation for relevant personnel.

Question 27

\"MediEquip Solutions,\" a manufacturer of surgical instruments, outsources the sterilization process to a third-party provider, \"SterilePro Services.\" During an internal audit of MediEquip\'s QMS, auditor Javier discovers that while MediEquip has a contract with SterilePro specifying sterilization parameters, there\'s no documented risk-based approach for evaluating SterilePro\'s ability to consistently meet these requirements, nor is there a process for ongoing monitoring of SterilePro\'s performance. Furthermore, SterilePro\'s QMS certification is outdated. According to ISO 13485:2016, what is the MOST critical action MediEquip Solutions must undertake to address this gap in their supplier management process, considering the potential impact on product safety and regulatory compliance? The CEO, Penelope, is keen to ensure the chosen approach is both effective and efficient.

Accepted Answer

Implement a documented, risk-based process for evaluating and monitoring SterilePro's performance, including periodic audits and performance data analysis, to ensure consistent compliance with specified sterilization parameters.

Question 28

\"MediCorp,\" a medical device manufacturer based in Switzerland, is preparing for its annual ISO 13485:2016 surveillance audit. The audit team, led by a seasoned auditor named Ingrid, focuses heavily on the documented information within MediCorp\'s Quality Management System (QMS). During the audit, Ingrid identifies several areas of concern: The quality manual does not clearly define the scope of the QMS, certain procedures lack documented evidence of periodic review, and work instructions on the assembly line are not consistently followed by the operators. Furthermore, the document control process does not adequately address the management of external documents, such as updated versions of the European Medical Device Regulation (MDR). Considering these findings and the requirements of ISO 13485:2016, what is the MOST critical action MediCorp must take to address these deficiencies and ensure compliance with the standard\'s documentation requirements?

Accepted Answer

Develop a comprehensive documentation strategy that includes a clearly defined quality manual, documented procedures with evidence of periodic review, standardized work instructions, and a robust process for managing external documents.

Question 29

BioTech Solutions, a manufacturer of implantable cardiac pacemakers, is undergoing an internal audit of their Quality Management System (QMS) based on ISO 13485:2016. The audit team, led by senior auditor Astrid Schmidt, is reviewing the company\'s risk management processes. During the review, Astrid notes that while the initial design risk assessment for the latest pacemaker model, \"PaceLife 3000,\" was comprehensive, there is limited evidence of incorporating post-market surveillance data into the ongoing risk management activities. Specifically, complaint data related to premature battery depletion in a small percentage of PaceLife 3000 devices has not been formally integrated into the risk assessment or risk control processes. Considering the requirements of ISO 13485:2016, which of the following findings would Astrid MOST likely highlight as a significant nonconformity during the audit?

Accepted Answer

Failure to integrate post-market surveillance data, such as complaint trends regarding premature battery depletion, into the risk management process to identify new or previously unrecognized hazards and update risk assessments accordingly.

Question 30

\"MediCorp Solutions,\" a medical device manufacturer specializing in implantable cardiac pacemakers, is undergoing an ISO 13485:2016 audit. During the audit, the lead auditor, Ms. Anya Sharma, observes that while MediCorp has meticulously documented risk assessments and control measures during the design and development phase of their latest pacemaker model, \"PaceLife X,\" the post-market surveillance activities appear limited to collecting complaint data without a systematic process for proactively identifying potential risks emerging from real-world usage. Specifically, there is no documented procedure for analyzing trends in adverse events or integrating this data back into the risk management process to update risk assessments. Moreover, supplier risk assessments are conducted only at the initial onboarding stage, with no periodic reviews to account for changes in supplier performance or regulatory landscape. Considering the requirements of ISO 13485:2016, what is the MOST significant area of non-compliance that Ms. Sharma should highlight in her audit report regarding MediCorp\'s risk management system?

Accepted Answer

The lack of a comprehensive risk management approach that extends beyond the design and development phase to include post-market surveillance and ongoing supplier risk assessment, resulting in a failure to proactively identify and mitigate potential risks throughout the entire product lifecycle.

ISO/IEC 17025:2017 - Testing and Calibration Laboratories Lead Auditor Free Practice Test — 30 Questions

A lot more is already mapped out

About the ISO/IEC 17025:2017 - Testing and Calibration Laboratories Lead Auditor Certification